Skip to content

US · AVLN · BIOTECHNOLOGY

Avalyn Pharma Inc. Common Stock (AVLN) intrinsic value and stock valuation

$28.40as of 2026-11-21 · Mkt cap 1.5B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Avalyn Pharma Inc. Common Stock DCF and intrinsic value

InvestorsCraft values AVLN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AVLN’s statements →

Avalyn Pharma Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02127 avalynpharma.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$0.00
20252025
Net income
-$-85.2M
20252025
Free cash flow
-$-81.83M
20252025
Total equity
-$-238.66M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$0.00
Operating income-$-91.29M
Net income-$-85.2M
EPSd-$-2.04M
Operating cash flow-$-81.48M
Capital expenditure-$-340K
Free cash flow-$-81.83M
Total assets$148.9M
Total debt$1.67M
Net debt-$-50.65M
Total equity-$-238.66M
Cash and short-term investments$138.4M
Income statement
2025
Revenue$0.00
Cost of revenue$0.00
Gross profit$0.00
Research and development expenses$76.6M
Selling, general and administrative expenses$14.7M
Other expenses$0.00
Operating expenses$91.3M
Cost and expenses$91.3M
Interest income$6.18M
Interest expense$0.00
Depreciation and amortization$40K
Ebitda-$-91.25M
Operating income-$-91.29M
Total other income/expenses, net$6.09M
Income before tax-$-85.2M
Income tax expense$0.00
Net income-$-85.2M
Weighted average shares outstanding$41.8M
Weighted average diluted shares outstanding$41.8M
Balance sheet
2025
Cash and short-term investments$138.4M
Net receivables$540K
Inventory$0.00
Total current assets$143.6M
Property, plant and equipment, net$2.32M
Goodwill and intangible assets$0.00
Long-term investments$0.00
Total non-current assets$5.32M
Total assets$148.9M
Accounts payable$3.76M
Short-term debt$440K
Deferred revenue$0.00
Total current liabilities$14.1M
Long-term debt$1.23M
Deferred revenue, non-current$0.00
Total non-current liabilities$373.5M
Capital lease obligations$1.67M
Total liabilities$387.5M
Common stock$20K
Retained earnings-$-265.36M
Accumulated other comprehensive income (loss)$130K
Total equity-$-238.66M
Total investments$86M
Total debt$1.67M
Net debt-$-50.65M
Cash flow statement
2025
Net income-$-85.2M
Depreciation and amortization$40K
Stock-based compensation$3.27M
Change in working capital$2.61M
Accounts receivable$0.00
Inventory$0.00
Accounts payable$1.4M
Net cash provided by operating activities-$-81.48M
Investments in property, plant and equipment-$-340K
Acquisitions, net$0.00
Net cash used for investing activities$10.1M
Common stock issued$20K
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$99.8M
Net change in cash$28.4M
Cash at end of period$52.3M
Operating cash flow-$-81.48M
Capital expenditure-$-340K
Free cash flow-$-81.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Avalyn Pharma Inc. Common Stock

        Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

        CEO
        Lyn Baranowski
        Employees
        50
        Beta
        -1.13

        Explore

        Frequently asked questions

        What is the intrinsic value of Avalyn Pharma Inc. Common Stock (AVLN)?

        InvestorsCraft does not currently publish an intrinsic value for AVLN. How the IC value is calculated.

        Is AVLN undervalued?

        InvestorsCraft does not publish an undervaluation signal for AVLN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.